Surgical · Other

Open surgical removal of a malignant tumor from the maxilla (upper jaw) or zygoma (cheekbone), using either an intraoral or extraoral approach.

Verified May 8, 2026 · 6 sources ↓

Medicare: $1,305.64
Total RVUs: 39.09
Global, days: 90
Region: Other

Drawn from CMSAAPCMdclarityCheckpointsurgical

Documentation requirements

What must appear in the operative or office note to support the claim.

Source · Editorial brief grounded in 6 cited references ↓

Pathology or biopsy report confirming malignant histology of the maxillary or zygomatic tumor
Operative note specifying surgical approach — intraoral vs. extraoral — and anatomic extent of resection
Imaging (CT or MRI) documenting tumor location, size, and bony involvement used for surgical planning
Margin status documentation or intraoperative frozen-section findings if performed
If modifier 22 is appended, a separate statement explaining how operative complexity exceeded the typical procedure
Anesthesia and facility records confirming setting, consistent with the procedure's complexity

Applicable modifiers

Modifiers commonly billed with this code.

Source · AMA CPT modifier descriptors · CMS NCCI Policy Manual

22 Increased complexity 51 Multiple procedures 52 Reduced services 57 Decision for surgery 58 Staged or related 59 Distinct service 62 Co-surgeons 74 Discontinued post-anesthesia 78 Unplanned return — related 79 Unrelated during global 80 Assistant surgeon LT Left side RT Right side

What this code covers

Source · Editorial summary grounded in 6 cited references ↓

CPT 21034 covers open excision of a confirmed malignant tumor arising from the maxilla or zygoma. The surgeon approaches the site either intraorally (through the mouth) or extraorally (through the skin), depending on tumor size, location, and extent of bony involvement. Reconstruction planning typically begins preoperatively; if bony reconstruction is performed at the same session, additional codes may apply.

This is a high-complexity craniofacial oncology procedure with a 90-day global period. All routine post-op visits, wound checks, and suture removal through day 90 are bundled — bill modifier 24 for unrelated E/M visits and modifier 79 for unrelated surgical procedures in that window. Per CMS NCCI policy, debridement within the surgical field is not separately reportable; only tissue debridement at an open fracture site may be billed separately.

The procedure is performed almost exclusively in a hospital outpatient or inpatient setting given anesthesia requirements and the need for oncologic margins. Maxillofacial surgeons and head-and-neck surgeons are the primary billers. Prior authorization is standard — document malignancy confirmation (pathology or biopsy report) and medical necessity before scheduling.

RVU & reimbursement

Component RVUs and Medicare national rate. Actual payment varies by GPCI locality.

Source · CMS Physician Fee Schedule, RVU26A · January 2026

Work RVU	16.95
Practice expense RVU	19.64
Malpractice RVU	2.5
Total RVU	39.09
Medicare national rate	$1,305.64
Global period	90 days

Payment by site of service

Medicare pays different rates by setting. HOPD typically pays substantially more than ASC for the same procedure.

Source · CMS OPPS Addendum B·ASC HCPCS payment rates·2026

Setting	Medicare rate (national)
Office (PFS non-facility) Procedure performed in physician's office	$1,305.64
HOPD (APC 5165) Hospital outpatient department	$6,048.05
ASC (PI A2) Ambulatory surgical center (freestanding)	$3,025.62

Common denial reasons

The recurring reasons claims for CPT 21034 get rejected.

Source · Editorial brief grounded in CMS NCCI edits, AAOS coding appeals, and cited references ↓

Malignancy not confirmed by pathology prior to claim submission — payers require histologic proof, not clinical suspicion
Missing or vague operative report that fails to identify the surgical approach or anatomic site by name
Bundling conflict when debridement within the surgical field is billed separately without a valid NCCI modifier
Prior authorization not obtained or obtained without documented biopsy results supporting medical necessity
Modifier 22 appended without an accompanying physician statement explaining the specific factors that increased complexity

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 6 cited references ↓

01What distinguishes 21034 from 21030?

21030 covers excision of a benign tumor of the maxilla or zygoma. 21034 is exclusively for malignant tumors. Using 21030 when pathology confirms malignancy is a miscode — confirm histology before selecting the code.

02Does the surgical approach (intraoral vs. extraoral) affect which code to bill?

No — both approaches map to 21034. Document the approach by name in the operative report anyway; audit teams flag notes that omit approach detail as insufficient to support a complex craniofacial resection.

03Can debridement be billed separately with 21034?

No. Per CMS NCCI policy, debridement of tissue within the surgical field of a bone excision procedure is bundled and not separately reportable. Only debridement at an open fracture site may be billed separately.

04When is modifier 62 appropriate for this procedure?

Modifier 62 applies when two surgeons of different specialties — for example, a maxillofacial surgeon and a head-and-neck oncologic surgeon — each perform a distinct part of the procedure requiring separate skills. Both surgeons must document their individual contributions in separate operative notes.

05Is prior authorization typically required?

Yes. Given the high RVU value and oncologic indication, most commercial payers and Medicare Advantage plans require prior authorization. Submit the biopsy report and imaging as part of the PA request to establish malignancy and medical necessity upfront.

06What happens if reconstruction is performed at the same operative session?

Reconstruction codes (such as bone graft or flap codes) may be separately reportable alongside 21034 if they represent distinct surgical services. Append modifier 51 for multiple procedures and document each service in the operative note. Verify NCCI edits for the specific reconstruction code pairing.

07Does the 90-day global period affect oncology follow-up billing?

Yes. Routine post-op visits within 90 days are bundled. If the patient is seen for cancer surveillance, radiation therapy planning, or a new problem unrelated to the surgery, append modifier 24 to the E/M code and document that the visit was unrelated to post-operative recovery.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

Mira AI Scribe

Mira's AI scribe captures the surgical approach (intraoral vs. extraoral), anatomic extent of bony resection, confirmation of malignant diagnosis referenced intraoperatively, and any reconstruction performed in the same session. That documentation prevents the most common denial for 21034: an operative note that fails to specify approach and extent, which auditors flag as insufficient to support the code's complexity and the 90-day global period.

See how Mira captures CPT 21034 documentation